Getty Images
In the first clinical trial of nicotinamide mononucleotide (NMN), researchers at Washington University School of Medicine in St. Louis have found that the compound previously demonstrated to counteract aspects of aging and improve metabolic health in mice also has clinically relevant effects in people.
A natural compound previously demonstrated to counteract aspects of aging and improve metabolic health in mice has clinically relevant effects in people, according to new research at Washington University School of Medicine in St. Louis.
A small clinical trial of postmenopausal women with prediabetes shows that the compound NMN (nicotinamide mononucleotide) improved the ability of insulin to increase glucose uptake in skeletal muscle, which often is abnormal in people with obesity, prediabetes or Type 2 diabetes. NMN also improved expression of genes that are involved in muscle structure and remodeling. However, the treatment did not lower blood glucose or blood pressur
COVID-19 survivors have increased risk of death for at least six months
As the COVID-19 pandemic has progressed, it has become clear that many survivors -; even those who had mild cases -; continue to manage a variety of health problems long after the initial infection should have resolved.
In what is believed to be the largest comprehensive study of long COVID-19 to date, researchers at Washington University School of Medicine in St. Louis showed that COVID-19 survivors -; including those not sick enough to be hospitalized -; have an increased risk of death in the six months following diagnosis with the virus.
ST. LOUIS Those who have had COVID-19 including those with mild cases have an increased risk of death in the six months following the diagnosis, according to research led by Washington University that is believed to be the largest comprehensive study yet on long-term complications related to the virus.
The study involved more than 87,000 COVID-19 patients and nearly 5 million control patients in a federal database. It was released online Thursday in the journal Nature.
The investigators showed that after the first 30 days of illness, COVID-19 survivors had an almost 60% increased risk of death over the following six months compared with the general population.
The researchers conducted the study in mice with breast cancer and one patient with late-stage pancreatic cancer.
The COVID-19 vaccines designed using bits of genetic information that prime our immune systems to recognize and fight off viral infections have become lifesavers in the global fight to end the pandemic.
Now, the new research has shown that a similar vaccine approach can be used to create personalized vaccines that program the immune system to attack malignant tumors, including breast and pancreatic cancers.
The tailor-made vaccines are designed to target mutated proteins called neoantigens that are unique to a patient’s tumors. Unlike the COVID-19 vaccines made by Moderna and Pfizer/BioNTech that rely on genetic material called mRNA, the personalized cancer vaccines are made using DNA.
COVID-19 survivors including those not sick enough to be hospitalised have an increased risk of death in the six months following diagnosis with the virus, according to the largest comprehensive study of long COVID-19 to date. The research, published in the journal Nature on Thursday, reveals the massive burden this disease is likely to place on the world s population in the coming years, they said. The researchers at Washington University School of Medicine in the US also have catalogued the numerous diseases associated with COVID-19, providing a big-picture overview of the long-term complications of COVID-19. They confirmed that, despite being initially a respiratory virus, long COVID-19 can affect nearly every organ system in the body.